Compare KARO & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KARO | KOD |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2020 | 2018 |
| Metric | KARO | KOD |
|---|---|---|
| Price | $60.91 | $98.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $73.89 | ★ $96.33 |
| AVG Volume (30 Days) | 49.6K | ★ 2.5M |
| Earning Date | 10-13-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.78 | N/A |
| Revenue Next Year | $15.55 | N/A |
| P/E Ratio | $24.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.25 | $10.94 |
| 52 Week High | $68.80 | $97.34 |
| Indicator | KARO | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 91.53 |
| Support Level | $43.75 | $24.96 |
| Resistance Level | $67.72 | N/A |
| Average True Range (ATR) | 2.38 | 5.70 |
| MACD | -0.72 | 8.12 |
| Stochastic Oscillator | 18.85 | 96.65 |
Karooooo Ltd is a provider of an operational intelligence platform. Through its cloud platform, the company enables fleet and asset management, fuel management, workforce management, logistics, safety, including AI-assisted video safety, compliance, risk, and environmental impact management. Its segments are: Cartrack, which generates the majority of revenue, provides an operational intelligence platform that maximizes the value of transportation, operations, and workflow data through insightful real-time data analytics to connected vehicles and equipment, and Karooooo Logistics provides a software application enabling the management of last-mile B2B delivery and general operational logistics (Delivery-as-a-Service or DaaS). It generates the majority of its revenue from South Africa.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.